The RPL23 expression levels in the lower- and higher-risk MDS patients were 1.05 ± 0.07 and 1.88 ± 0.17, respectively (p < 0.001), and the c-Myc expression levels were 1.03 ± 0.07 and 1.86 ± 0.09 in the lower- and higher-risk MDS patients, respectively (p < 0.001). This evidence concerns the gene MYC and myelodysplastic syndrome.